

INDEPENDENT AUDITOR'S REVIEW REPORT

TO THE BOARD OF DIRECTORS OF CAMSON BIO TECHNOLOGIES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **CAMSON BIO TECHNOLOGIES LIMITED** ("the Company") for the quarter and six months ended September 30, 2016 and the Standalone Unaudited Statement of Assets and Liabilities as at September 30, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Because of the matter described in paragraph 3 below, we were not able to obtain sufficient appropriate evidence to state whether the Statement is free of material misstatement.
3. We draw attention to Note 3 of the Statement. The Company has received communication from shareholders to conduct a forensic audit on the financial matters of the Company. The Company has replied to the said shareholder requesting specific facts and scope/areas for the forensic audit. The Company's Board of Directors has proposed to carry out a forensic audit by appointing an independent committee/legal counsel. As stated in the aforesaid Note, the Company is of the view that material adjustments or disclosures, if any, arising out of the forensic audit would be considered after conclusion of the forensic audit and the Management has not estimated the impact of any adjustment that may arise to the amounts and disclosures in the Statement. Consequently, we have not been able to state whether any adjustments or disclosure would be required to the information included in the Statement and the impact thereof.



**Deloitte
Haskins & Sells LLP**

4. Because of the significance of the matter described in paragraph 3 above, we do not have a basis to state whether the Statement is prepared in accordance with the aforesaid Accounting Standard and other accounting principles generally accepted in India and whether the statement has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Bangalore
Date: November 10, 2016

For Deloitte Haskins & Sells LLP
Chartered Accountants
Firm's Registration No. 117366W/W-100018

A handwritten signature in black ink, appearing to read "S. Ganesh".

S. Ganesh
Partner
Membership No. 204108

CAMSON BIO TECHNOLOGIES LIMITED
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2016

Rupees in Lakhs

Sl. No.	Particulars	Standalone						Previous Year Ended 31st March 2016
		Quarter Ended		Half year Ended		Refer Note 3		
		30th September 2016 (Unaudited)	30th June 2016 (Unaudited)	30th September 2015 (Unaudited)	30th September 2016 (Unaudited)			
1	Income from Operations							
	(a) Net sales / income from Operations	219.07	205.05	1,225.62	424.12	2,649.23	2,540.33	
	(b) Other Operating Income	-	-	-	-	-	-	
	Total Income from Operations (net)	219.07	205.05	1,225.62	424.12	2,649.23	2,540.33	
2	Expenses							
	(a) Cost of Materials consumed	42.58	19.43	286.94	62.01	365.62	574.81	
	(b) Purchase of stock- in-trade	-	-	-	-	-	-	
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	37.53	74.10	(211.01)	111.63	(99.64)	(91.23)	
	(d) Employee benefits expenses	150.36	156.77	304.33	307.13	576.93	992.40	
	(e) Depreciation and amortisation expenses	188.97	187.20	269.97	376.17	546.56	2,171.77	
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	-	-	-	-	-	-	
	i Geo - Climatic Trials	20.55	24.71	140.39	45.26	244.91	402.86	
	ii Selling and Promotion Expenses	105.67	199.70	164.73	305.37	393.78	969.43	
	iii Other Expenses	161.67	158.48	333.63	320.15	576.92	1,129.92	
	Total Expenses	707.33	820.39	1,288.98	1,527.72	2,605.08	6,149.96	
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(488.26)	(615.34)	(63.36)	(1,103.60)	44.15	(3,609.63)	
4	Other Income	58.66	52.97	82.07	111.63	88.53	115.75	
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(429.60)	(562.37)	18.71	(991.97)	132.68	(3,493.88)	
6	Finance Costs	101.59	111.51	119.89	213.10	176.81	498.90	
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(531.19)	(673.88)	(101.18)	(1,205.07)	(44.13)	(3,992.78)	
8	Exceptional Items	-	-	-	-	-	-	
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(531.19)	(673.88)	(101.18)	(1,205.07)	(44.13)	(3,992.78)	
10	Tax Expenses	16.18	17.32	(38.46)	33.50	23.92	(209.30)	
11	Net Profit / (Loss) from Ordinary Activities after tax (9 + 10)	(547.37)	(691.20)	(62.72)	(1,238.57)	(66.05)	(3,783.48)	
12	Extraordinary items (net of tax expenses)	-	-	-	-	-	-	
13	Net Profit / (Loss) for the period (11 + 12)	(547.37)	(691.20)	(62.72)	(1,238.57)	(66.05)	(3,783.48)	
14	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98	
15	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year	-	-	-	-	-	7,473.65	
16.i	Earnings per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs							
	(a) Basic	(1.82)	(2.30)	(0.21)	(4.12)	(0.23)	(12.61)	
	(b) diluted	(1.82)	(2.30)	(0.21)	(4.12)	(0.23)	(12.61)	
16.ii	Earnings per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs							
	(a) Basic	(1.82)	(2.30)	(0.21)	(4.12)	(0.23)	(12.61)	
	(b) Diluted	(1.82)	(2.30)	(0.21)	(4.12)	(0.23)	(12.61)	
	See accompanying note to the Financial Results							



STATEMENT OF ASSETS AND LIABILITIES UNDER CLAUSE 41(v) OF THE LISTING AGREEMENT

Rupees in Lakhs

Sl. No	PARTICULARS	Standalone	
		30th September 2016 (Unaudited)	31st March 2016 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	2,999.98	2,999.98
	(b) Reserves and surplus	6,185.09	7,423.65
	(c) Money received against share warrants	-	-
	Sub Total - Shareholders funds	9,185.07	10,423.63
2	Non-current liabilities		
	(a) Long term borrowings	944.90	948.55
	(b) Other long term liabilities	196.95	228.85
	(c) Deferred tax liabilities (net)	-	-
	(d) Long term provisions	59.39	55.39
	Sub Total - Non current liabilities	1,201.24	1,232.79
3	Current liabilities		
	(a) Short term borrowings	3,673.29	3,638.35
	(b) Trade payables	789.76	768.02
	(c) Other current liabilities	1,066.76	844.36
	(d) Short term provisions	444.96	709.36
	Sub Total - Current liabilities	5,974.77	5,960.09
	TOTAL	16,361.08	17,616.51
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	10,185.66	10,561.91
	(b) Intangible asset under development	-	-
	(c) Non-current investments	597.91	597.91
	(d) Deferred tax assets (net)	84.64	118.14
	(e) Long term loans & advances	2,830.57	3,256.71
	(f) Other non-current assets	0.50	7.50
	Sub Total - Non-current assets	13,699.28	14,542.17
2	Current Assets		
	(a) Inventories	1,249.60	923.94
	(b) Trade receivables	1,223.49	2,074.29
	(c) Cash & cash equivalents	26.91	30.21
	(d) Short term loans & advances	161.80	45.90
	(e) Other current assets	-	-
	Sub Total - Current assets	2,661.80	3,074.34
	TOTAL	16,361.08	17,616.51



Notes :

1. The above unaudited financial results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 10th November 2016.
2. The nature of the Company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the Company on quarter to quarter can vary significantly and are therefore not comparable.
3. During the previous year, the company has received communication from shareholders to conduct a forensic audit on the financial matters of the Company. The Company's Board of Directors on meeting held on Aug 11, 2016 has decided the scope of forensic audit and appointed an independent firm for conducting the same. Accordingly, the company is of the view that material adjustments or disclosures, if any, would be considered after conclusion of the forensic audit.
4. The Company's operation comprise only of one segment viz., Agri Biotech Products.
5. Figures for the previous periods/year have been regrouped / rearranged wherever necessary.

Place: Bangalore

Date : 10th November 2016



For and on behalf of the Board of Directors

A handwritten signature in black ink, appearing to read "Veerendra Kumar Singh".

Veerendra Kumar Singh
Managing Director

